Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sentinel Lymph Node Biopsy for Eyelid Sebaceous Gland Carcinoma
NCT00832429Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2009
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of technetium tc 99m sulfur colloid in sebaceous gland carcinoma of the eyelid (SGC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Sentinel Lymph Node Positivity at 1 year and False negative events associated with SLN biopsy at 1 year. Started Feb 2009; status: completed.
02
Drugs
technetium tc 99m sulfur colloid
03
Conditions
sebaceous gland carcinoma of the eyelid (SGC)
Beyond the preview
Go deeper on NCT00832429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00832429.